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Abstract
Proteomic studies with different Staphylococcus aureus isolates have shown that the cell
surface-exposed and secreted proteins IsaA, LytM, Nuc, the propeptide of Atl (pro-Atl) and
four phenol-soluble modulins α (PSMα) are invariantly produced by this pathogen. There-
fore the present study was aimed at investigating whether these proteins can be used for
active immunization against S. aureus infection in mouse models of bacteremia and skin in-
fection. To this end, recombinant His-tagged fusions of IsaA, LytM, Nuc and pro-Atl were
isolated from Lactococcus lactis or Escherichia coli, while the PSMα1-4 peptides were
chemically synthesized. Importantly, patients colonized by S. aureus showed significant im-
munoglobulin G (IgG) responses against all eight antigens. BALB/cBYJ mice were immu-
nized subcutaneously with a mixture of the antigens at day one (5 μg each), and boosted
twice (25 μg of each antigen) with 28 days interval. This resulted in high IgG responses
against all antigens although the response against pro-Atl was around one log lower com-
pared to the other antigens. Compared to placebo-immunized mice, immunization with the
octa-valent antigen mixture did not reduce the S. aureus isolate P load in blood, lungs,
spleen, liver, and kidneys in a bacteremia model in which the animals were challenged for
14 days with a primary load of 3 × 105 CFU. Discomfort scores and animal survival rates
over 14 days did not differ between immunized mice and placebo-immunized mice upon
bacteremia with S. aureus USA300 (6 × 105 CFU). In addition, this immunization did not re-
duce the S. aureus isolate P load in mice with skin infection. These results show that the tar-
get antigens are immunogenic in both humans and mice, but in the used animal models do
not result in protection against S. aureus infection.
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Introduction
Staphylococcus aureus is a widespread Gram-positive bacterium that colonizes the skin and an-
terior nares of about 20–30% of the healthy human population [1]. Although mainly a harm-
less colonizer, S. aureus can cause invasive diseases like skin and soft tissue infections, and can
be responsible for severe infections in humans like pneumonia, endocarditis and osteomyelitis
[1], which are frequently associated with S. aureus bacteremia [2]. S. aureus in its methicillin-
resistant form (MRSA) is the most important cause of antibiotic-resistant health care-associat-
ed infections worldwide [3,4]. In the case of MRSA, a single genetic element makes S. aureus
resistant to the most frequently prescribed class of antimicrobials—the β-lactam antibiotics, in-
cluding penicillins, cephalosporins, and carbapenems [5]. A high incidence of MRSA is en-
countered in hospitals, resulting in prolonged hospital stays and in higher mortality rates [3,4],
and limited effectiveness of alternative treatment regimens. Glycopeptides, especially vancomy-
cin, are currently used as first-line treatment of MRSA infections. Unfortunately, this has led to
the emergence of vancomycin-intermediate and vancomycin-resistant MRSA [6]. In addition,
there is raising concern that the current first-line treatment for MRSA infection will become in-
creasingly ineffective. Since in the past 25 years no novel small-molecule antibacterial drugs
have been discovered [7], and the development pipeline of new antimicrobials remains lean
[8], new ways of treatment of S. aureus infections such as immunization need to be explored.
Several strategies of passive and active immunization in S. aureus infections have been studied
in experimental infection models, but until now none of these have been proved to be effective
in clinical studies [9–11]. Insufficient power because of a low sample size in some clinical stud-
ies [12,13], as well as the heterogeneity of S. aureus strains causing infections in humans
[14,15] may contribute to the failure of treatment through immunization in patients. Despite
the lack of success so far, immunization approaches are still worth pursuing especially in pa-
tients admitted to the hospital for elective surgery. For this group of patients, there may be
enough time for immunization prior to surgery.
Novel target identification strategies have been applied to screen for new antigenic targets
for immunization. Invariant immunogenic determinants of relevant S. aureus isolates have
been successfully identified in previous studies using a combination of proteomics, genomics,
bioinformatics and immunological approaches [15–18]. A complete inventory of predicted se-
creted proteins of sequenced S. aureus strains has been made [16]. Proteomic analysis of the
exoproteomes of 25 clinical S. aureus isolates showed that only seven of these secreted proteins
(IsaA, Lip, LytM, Nuc, SA0620, SA2097, and SA2437) were produced by all clinical isolates
studied [15]. In a proteolytic shaving approach of S. aureus cells, multiple surface-exposed pro-
teins were identified among which IsaA, Nuc, Atl and the phenol-soluble modulin (PSM) α1
peptide [17].
In the present study, we used IsaA, LytM, Nuc, pro-Atl, and the PSMα1-4 peptides as targets
for active immunization in S. aureus-infected mice. These S. aureus antigens were all selected
by the previous target identification strategies, and are all potential virulence factors of S. aure-
us. The PSMs are highly potent surfactants that facilitate the movement of S. aureus over moist
surfaces by colony spreading, and they are involved in the metastatic escape of staphylococcal
cells from biofilms thereby representing an enormous risk factor for serious invasive disease
[19,20]. High levels of PSM production are supposed to contribute to the high virulence and
epidemic behavior of community-acquired MRSA lineages [21].
Staphylococcal major autolysin (Atl) is a bifunctional autolysin composed of a signal pep-
tide for protein secretion, a propeptide, and domains with amidase and glucosaminidase activi-
ty. After proteolytic cleavage, the active domains are involved in cell separation and they have
been shown to be cell surface-exposed [22]. It is believed that the propeptide of Atl (pro-Atl)
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has a role in the folding and/or activation of Atl and that it would be degraded rapidly upon
proteolytic processing of the Atl protein.
Immunodominant staphylococcal antigen A (IsaA) and autolysin M (LytM) have been
shown to be peptidoglycan hydrolases with transglycosylase and glycyl-glycine endopeptidase
specific activity, respectively [18]. The secreted nuclease (Nuc) has been shown to limit the for-
mation of biofilms due to the degradation of extracellular DNA [23]. This protein also pro-
motes resistance against neutrophil extracellular traps-mediated antimicrobial activity of
neutrophils and thus contributes to disease pathogenesis in vivo [24].
In previous studies, IsaA, LytM, Nuc, pro-Atl and PSMα1-4 have all been shown to be im-
munogenic. Using a multiplex assay to quantify antibody responses against 26 staphylococcal
proteins, we found that mice with a S. aureusUSA300 pneumonia or skin infection showed
good IgG responses against IsaA and Nuc, while anti-LytM levels were low [25]. In contrast, in
mice immunized with monovalent staphylococcal vaccines containing IsaA, Nuc or LytM, the
highest IgG responses were obtained against the latter antigen. Using the same multiplex assay,
it has been shown that 75% of the patients with the genetic blistering disease epidermolysis bul-
losa (EB), who were heavily colonized with multiple S. aureus types, have increased IgG re-
sponses against some secreted, cell wall and membrane-bound staphylococcal proteins [26,27].
Importantly, EB patients do not frequently suffer from S. aureus bacteremia, which suggests
that their high anti-staphylococcal antibody titers might be protective against invasive S. aureus
infections. Within the EB patient group, the highest response was detected against IsaA, while
for Nuc and LytM moderate responses were detected. These data show that both in mice and
in human individuals a good IgG response is generated against IsaA, LytM and Nuc. Moreover,
passive immunization of mice with murine anti-IsaA resulted in protection against staphylo-
coccal infection both in a central venous catheter-related infection model and a sepsis survival
model, most likely due to phagocytosis that resulted in killing of S. aureus [28]. Holtfreter et al.
showed in their review that Atl has been identified in different studies as a well-recognized tar-
get of the human immune system [29]. Recently, we showed that pro-Atl is exposed on the out-
side of S. aureus cells and is recognized by antibodies from four out of six patients that were
colonized with S. aureus (our unpublished observations). Within a patient group of hospital-
ized adults with an invasive S. aureus infection, in those patients who did not develop sepsis,
higher levels of immunoglobulin G (IgG) responses were detected against exotoxins among
which PSMα3 [30].
In the present study in mice, we examined the protective efficacy of active immunization
with an octa-valent antigen mixture containing IsaA-His6, LytM-His6, Nuc-His6, His6-pro-Atl
and the PMSα1–4 peptides. In mice immunized with a mixture of these antigens, the generated
IgG response was determined by enzyme-linked immunosorbent assays (ELISA). Subsequent-
ly, the protective capacity of this immunization strategy was studied in mouse models of methi-
cillin-sensitive S. aureus (MSSA) or MRSA bacteremia and in a mouse model of MSSA skin
infection, which are clinically highly relevant S. aureus infections [31].
Materials and Methods
Bacterial strains and growth conditions
Strains and plasmids used in this study are listed in Table 1. Lactococcus lactis strains were
grown at 30°C in M17 broth (Oxoid Ltd, Hampshire, UK) supplemented with 0.5% w/v glucose
(GM17). When necessary the medium was supplemented with chloramphenicol (5 μg/mL) for
plasmid selection. For in vivo studies, S. aureus isolate P and USA300 were used and grown in
Brain Heart Infusion broth (Becton Dickinson, Breda, the Netherlands). S. aureus isolate P is a
community-acquired MSSA strain recovered from the blood of a septic patient and was
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previously analyzed by proteomics [15]. S. aureusUSA300 is one of the most frequent causes
of community-acquired infections in the United States of America [32].
Construction of His6-pro-Atl expression plasmids
For cloning of the DNA fragment coding for the propeptide of Atl (pro-Atl) in the plasmid
pNG4110, the primers atlpro.F1 (ATATGGATCCGCTGAGACGACACAAGATCAAACTAC-
TAATAAAAACG) and atlpro.R2 (ATATGCGGCCGCTTAAGCGCTAAAAGTAGTTACTT-
TAGGTGTCGCTTCAGTTTTAGC) were used with chromosomal DNA of S. aureus strain
N315 as a template. Using this vector, a N-terminally His-tagged fusion protein can be secreted
from L. lactis [33]. PCR product and vector were digested using BamHI andNotI (cleavage sites
are underlined in the primers sequences). After ligation the resulting plasmids were transferred
into L. lactis PA1001 by electro transformation with selection on chloramphenicol. A nucleotide
sequence analysis of the cloned inserts was performed by Eurofins DNA (Ebersberg, Germany).
Protein isolation, purification and quantification
For the production and isolation of IsaA-His6, an overnight culture of E. coli BL21DE3
(pET24d::isaA::his6) was diluted 1:100 in fresh lysogeny broth with 50 μg/mL kanamycin [34].
Induction was performed at OD600 ~ 0.5 for 4 h by adding 1 mM isopropyl β-D-1-thiogalacto-
pyranoside (IPTG) (Duchefa, Haarlem, the Netherlands). The culture was centrifuged and the
pellet was resolved in binding buffer (20 mM Na-Phosphate, pH 7.4, 0.5 M NaCl2, 60 mM im-
idazole) containing 6 M urea. After sonification (Sonicator S-4000, Misonix, Farmingdale,
USA) the supernatant was mixed with binding buffer (1:1) and HisLink beads (Promega,
Madison, USA) for 1 h at 4°C under shaking conditions. Protein elution was performed with
binding buffer containing 500 mM imidazole.
For the production and isolation of LytM-His6 [25], Nuc-His6 [25] and His6-pro-Atl, over-
night cultures of L. lactis PA1001 were diluted 1:2 in GM17 medium. Nisin induction for pro-
tein expression was performed at OD600 ~ 0.5 for 16 h by adding the culture supernatant
(1:1000) from an overnight culture of L. lactis NZ97000. For analysis of the extracellular pro-
duction of His6-pro-Atl by L. lactis PA1001 (pNG4110::proAtl), proteins from the culture
Table 1. Bacterial strains and plasmids used in this study.
Strain or plasmid Relevant phenotype(s) or genotype(s) Source or reference
Strains
E. coli BL21DE3 Allows IPTG-inducible expression of PT7 Novagen
L. lactis NZ9700 Nisin producer [63]
L. lactis PA1001 MG1363 pepN::nisRK, allows nisin inducible expression, ΔacmA ΔhtrA [64]
S. aureus isolate P Community-acquired MSSA patient isolate [15]
S. aureus USA300 Community-acquired MRSA isolate [32]
S. aureus N315 Hospital-acquired MRSA [65]
Plasmids
pET24d::isaA::his6 Kan
R, pET24d containing isaA with C-terminal his6 [34]
pPA180::lytM::his6 Cm
R, pPA180 containing lytM with C-terminal his6 [25]
pNG400::nuc::his6 Cm
R, nisin inducible expression via PnisA of Nuc with C-terminal his6 [34]
pNG4110::proAtl CmR, nisin inducible expression via PnisA of the pro-Atl peptide fused to SSusp45, and a N-terminal his6 This study
KanR, kanamycin resistance gene; CmR, chloramphenicol resistance gene; PT7, IPTG inducible T7-promoter; PnisA, nisin inducible promoter; his6, 6
histidine-tag; SSusp45, signal sequence of usp45.
doi:10.1371/journal.pone.0116847.t001
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supernatant were precipitated using trichloroacetic acid (TCA; 10% w/v). The culture was cen-
trifuged and the pellet was washed with acetone and dried. For the isolation of Nuc-His6, from
the supernatant fraction of a culture of L. lactis PA1001 (pNG400::nuc::his6), HisLink beads
were added for 1 h at 4°C under shaking conditions after which HisLink beads were collected.
For isolation of LytM-His6 cells of L. lactis PA1001 (pPA180::lytM::his6) were harvested and
disrupted in binding buffer using a Sonicator S-4000. Purification was performed with Mag
beads (GE Healthcare, Uppsala, Sweden) for 1.5 h under shaking conditions at 4°C. Elution of
Nuc-His6 and LytM-His6 was done with binding buffer containing 500 mM imidazole. The
flow-through, wash and elution fractions were analyzed by LDS-PAGE. Protein samples were
mixed with LDS buffer and incubated at 95°C for 10 min, separated by LDS-PAGE using pre-
cast 10% NuPage gels (Life Technologies, Bleiswijk, the Netherlands) and stained with Simply
Blue™ Safe Stain (Life Technologies).
The fractions containing the purified His-tagged proteins of IsaA-His6, LytM-His6, Nuc-
His6 or His6-pro-Atl were pooled and dialyzed (G2-Float-A-Lyzer, Spectrum Europe BV,
Breda, the Netherlands) against PBS and concentrated with the Speedvac Concentrator Plus
(Eppendorf Nederland BV, Nijmegen, the Netherlands).
Protein concentrations were determined with the DC Protein Assay (Bio-Rad, Veenendaal,
the Netherlands) according to the instructions of the supplier, using Bovine Serum Albumin
(Sigma-Aldrich, Zwijndrecht, the Netherlands) as a standard, or with the Nanodrop ND-1000
(Thermo Fisher Scientific, Wilmington, Delaware USA) using the extinction coefficient calcu-
lated for each of the proteins.
PSMα1-4 were synthesized as described previously [19], with the addition of a GGG-Lys(ε-
biotin). The peptides were mixed in a 1:1:1:1 molar ratio, and incubated in PBS in a stoichio-
metric ratio to avidin (Thermo Fisher Scientific Inc., Rockford, USA).
Human plasma
Whole blood donations from EB patients were collected under the approval of the medical ethics
committee of the University Medical Center Groningen (approval no. NL27471,042,09) upon writ-
ten informed patient consent, and with adherence to the Helsinki Guidelines [26]. The Indepen-
dent Ethics Committee of the Foundation ‘Evaluation of Ethics in Biomedical Research’ (Assen,
the Netherlands), approved the protocol for blood donations from healthy volunteers. This proto-
col is registered by QPS Groningen (code 04132-CS011). The required written informed consent
was obtained from all EB patients and healthy volunteers included in the present studies.
Protein detection and activity assays
For Western blot analyses, proteins separated by LDS-PAGE were blotted onto a nitrocellulose
membrane (Protran, Schleicher & Schuell BioScience, Dassel, Germany). Immunodetection
was performed using anti-His-tag antibodies (Invitrogen, Life Technologies) and rabbit poly-
clonal antibodies raised against the amidase or glucosaminidase domains of Atl (gift from
Motoyuki Sugai, Hiroshima University, Japan [35]). Dilutions (1:1000) of the collected human
plasma [26] were used to detect the IgG responses against IsaA-His6, LytM-His6 and Nuc-His6.
Equal amounts of the three proteins were loaded on the gel and after blotting strips of the blot
were incubated with the different plasma samples. Bound primary antibodies were visualized
using specific fluorescently labeled secondary antibodies (IRDye 800 CW, Li-Cor Biosciences,
Lincoln, USA). Membranes were scanned for fluorescence at 800 nm using the Odyssey Infra-
red Imaging System (Li-Cor Biosciences, Nebraska, USA).
To show expression of the PSMα1-4 peptides by S. aureus isolates P and USA300, both strains
were tested for the ability to spread on tryptic soy soft agar (TSA) plates (0.24% agar). From an
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overnight culture, an aliquot of 2 μL was spotted in the middle of a TSA plate, which was then in-
cubated overnight at 37°C. The spreading assay was performed as described [19,36].
Peptidoglycan hydrolase activity of IsaA-His6 and LytM-His6 was detected by a zymogram
staining technique using SDS-polyacrylamide (12.5%) gels containing 0.1% (w/v) autoclaved
cell wall fragments of S. aureus RN4220 isolated as described previously [37]. After electropho-
resis, the gels were gently shaken at room temperature for 24 h in three to five changes of 100 mL
of 25 mMTris-HCl (pH 6.0) containing 1% (v/v) Triton X-100 for protein renaturation.
Pepscan analysis
To determine whether regions of the S. aureus PSMα1-4 peptides were recognized by human
IgGs, libraries of linear 15-mer peptides were synthesized with an overlap on solid support
(Pepscan), as previously described [38]. The peptide libraries were probed with heat-inacti-
vated human sera, in a dilution of 1:1000, with goat-anti-human-HRP conjugate (SouthernBio-
tech, Birmingham, USA) as a secondary antibody, and developed with 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid (Sigma-Aldrich). A charge-coupled device camera was
used to register absorbance at 405 nm. For every single Pepscan dataset, the data were normal-
ized to the average signal intensity of the analysis. Furthermore, the signals for every single pro-
tein were normalized to the median of the corresponding protein. In addition the standard
deviations of the normalized data sets were calculated for each protein. Peptides with a signal
exceeding the median plus twice the standard deviation and normalized signal intensity higher
than three were regarded as being immunogenic domains.
Animals
Specified pathogen-free female BALB/cBYJ mice were obtained from Charles River (Saint-Ger-
main-sur-l’Arbresle, France). Mice were housed in individually ventilated cages, 3–4 mice per cage.
Animals were 11–13 weeks old at the day of infection, and were given food and water ad libitum.
All animal experiments were performed in accordance with the rules laid down in the Dutch Ani-
mal Experimentation Act and the EU Animal Directive 2010/63/EU (permit number: EMC2694).
Immunization procedure
Purified Nuc-His6, LytM-His6, IsaA-His6, His6-pro-Atl, and PSMα1-4 were emulsified 1:1 with
TiterMax Gold adjuvant (Sigma-Aldrich). Mice were immunized subcutaneously in the flank
with 100 μL formulated vaccine on days -70 (5 μg of each antigen), days -42, and -14 (25 μg of
each antigen). PSMα1-4 was considered as a single antigen, and therefore a total of 5 or 25 μg
of this 1:1:1:1 mixture was used per immunization. Control mice received 100 μL PBS emulsi-
fied with adjuvant. Mice were randomly allocated to either the vaccine or the placebo group. At
days -71 and -1, blood was withdrawn from the tail artery. Sera were examined by ELISA for
IgG titers with specific antigen-binding activity.
ELISA
ELISA plates (Greiner Bio-One B.V, Alphen aan den Rijn, the Netherlands) were coated with
250 ng of the antigens in coating buffer (0.05 M carbonate-bicarbonate, pH 9.6–9.8) and incubat-
ed for three days at 4°C. The plates were blocked for 45 min at 37°C in coating buffer with 2.5%
milk powder (Oxoid, Hampshire, UK). After washing, serial twofold dilutions of the sera were
made in PBS containing 0.05% Tween-20 (PBST) and incubated for 2 h at 37°C. After washing
with PBST, the plates were incubated with GaM/IgG-HRP (SouthernBiotech) (1:5000 in PBST)
for 90 min at 37°C. Finally, the peroxidase reaction was visualized using o-phenylene-diamine
Immunization with an Antigen Mixture in S. aureus Infection Models
PLOS ONE | DOI:10.1371/journal.pone.0116847 February 24, 2015 6 / 20
(Sigma-Aldrich) for 30 min at room temperature. The reaction was stopped by adding 2 M
H2SO4. The plates were measured at 492 nm in a plate reader (Biotek Powerwave XS2, Beun de
Ronde, Abcoude, the Netherlands).
Infection model of S. aureus bacteremia
Immunized mice (n = 8 per group) were challenged on day 0 by intravenous inoculation of
100 μL of S. aureus isolate P (3 × 105 CFU) or S. aureus USA300 (6 × 105 CFU) as described
previously [39]. Discomfort and animal survival rate over 14 days after infection were moni-
tored. For discomfort score, clinical signs of illness in each mouse were evaluated at least twice
daily as described before [39]. Mice were scored -1 directly after bacterial inoculation. Mice with
bad fur were scored -2. Mice with bad fur and hunched back were scored -3. Mice with bad fur
and hunched back and that were instable were scored -4. These mice showed severe signs of ill-
ness and were euthanized by CO2 exposure. At day 14 after infection in surviving mice, S. aureus
load in blood, lungs, spleen, liver and kidneys was determined. Mice were sacrificed by CO2 expo-
sure and exsanguinated by cardiac puncture. Blood was collected in a vial containing Lithium
Heparin (Sarstedt, Etten-Leur, the Netherlands). Organs were removed aseptically and homoge-
nized using a gentleMACS™Dissociator (Miltenyi Biotec, Leiden, the Netherlands) in 2 mL of sa-
line. CFUs of (un-)diluted blood and organ homogenates were determined after overnight
growth on trypticase soy agar with 5% sheep blood (Becton Dickinson).
Infection model of S. aureus skin infection
Immunized mice (n = 4 per group) were challenged on day 0 by intradermal inoculation of S.
aureus isolate P. The method of induction of S. aureus skin infection in mice was adapted from
Brown et al. [40]. In short, the lower back of the mice was shaved and cleaned with 70% ethanol
under general anesthesia after using a mixture of medetomidine (Sedator
1
, 0.5 mg/kg; Eurovet
Animal Health, Bladel, the Netherlands), midazolam (Midazolam, 5 mg/kg; Actavis, Baarn, the
Netherlands) and fentanyl (Fentanyl, 0.05 mg/kg; Hameln Pharmaceuticals, Hameln, Ger-
many). S. aureus isolate P (3 × 107 CFU) was injected intradermally (50 μL). The mice were an-
tagonized using a mixture of atipamezole (Antisedan
1
, 2.5 mg/kg; Orion Corporation, Espoo,
Finland), flumazenil (Flumazenil, 0.5 mg/kg; Pharmachemie, Haarlem, the Netherlands) and
naloxon (Naloxon, 1.2 mg/kg; Orpha-Devel Handels und Vertriebs, Purkersdorf, Germany).
Anesthetic and antagonistic agents were administered intraperitoneally, in a total volume of
175 and 250 μL, respectively. Animal body weight and lesion size over 7 days after infection
were monitored. Lesions were measured with a caliper. Lesion size was calculated by using the
formula A = π(L ×W)/2, where L is length andW is width of the lesion [41]. At day 7 after in-
fection, mice were sacrificed by CO2 exposure. A circular area (diameter 14 mm) of the skin le-
sion was removed aseptically and homogenized using a gentleMACT™ Dissociator in 2 mL
saline. Serial dilutions of skin homogenates were cultured on phenol-red mannitol salt agar
(Becton Dickinson). Culture plates were incubated at 35°C for 48 h and at room temperature
for 5 days. Identification of S. aureus was based upon colony morphology on the PHMA. Sus-
pected colonies were cultured overnight on trypticase soy agar with 5% sheep blood (Becton
Dickinson). A latex agglutination test (Staph Plus Latex; DiaMondial, Vienna, Austria) was
then performed. The primary outcome measure was a reduction in S. aureus load in the skin le-
sion, secondary outcome measures were animal body weight and skin lesion size over time.
Statistical analysis
The Mann-Whitney U test was used to compare median differences in bacterial load in differ-
ent groups. The log rank test was used to determine statistical differences in animal survival
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rate between groups. Correlations between IgG titers and time-to-death were assessed using Pear-
son’s correlation coefficient. GraphPad Prism 5 for Windows (GraphPad Software Inc., La Jolla,
CA) was used for these statistical analyses. Quade’s rank analysis of covariance was used to com-
pare discomfort score, skin lesion size and body weight in different groups over time. These statis-
tical analyses were performed using the Statistical Package of Social Sciences version 17.0 for
Windows (SPSS Inc., Chicago, IL). P-values< 0.05 were considered to be statistically significant.
Results
Isolation and purification of S. aureus antigens
In a recent study on epitope mapping of surface proteins of S. aureus, the N-terminal propep-
tide of Atl (pro-Atl) was shown to be cell surface exposed (our unpublished observations).
Therefore, this protein domain was chosen as a candidate target for the screening of human an-
tibodies against S. aureus. After cloning, the His6-pro-Atl fusion protein was produced by L.
lactis and expression and secretion of the peptide was proven by comparing the cell and growth
medium fractions of nisin-induced and non-induced cultures using LDS-PAGE analysis as pre-
viously described [34] (data not shown). Western detection confirmed that this recombinant
protein contained the His-tag needed for its isolation (data not shown).
The S. aureus antigen IsaA-His6 was isolated from E. coli, whereas LytM-His6, Nuc-His6,
and His6-pro-Atl were isolated from L. lactis to avoid possible cloning, degradation and expres-
sion problems [34]. The isolated and purified His-tagged proteins were verified using LDS-
PAGE and subsequent protein staining (Fig. 1). Using zymographic analysis it was shown that
purified LytM-His6 and IsaA-His6 had retained their enzymatic peptidoglycan-degrading ac-
tivity while Nuc-His6 was still able to hydrolyze DNA [34]. The individual and pooled synthetic
PSMα1-4 peptides were shown to facilitate the spreading motility of a non-motile S. aureus
strain that cannot produce these peptides [36], indicating that they are biologically active [19].
These data show that the antigens were successfully isolated or synthesized and that the IsaA-
His6, LytM-His6, and Nuc-His6 fusions had retained their enzymatic activities.
Production of antigens by S. aureus isolate P and USA300
To show the production of the selected antigens by the S. aureus isolates P (MSSA) and
USA300 (MRSA) that were used in the in vivo studies, different protein detection methods
were used. For S. aureus USA300 all antigens used in this study had been identified in earlier
(proteomics) studies (Table 2). Also for the S. aureus isolate P, most of the antigens were iden-
tified by proteomics in earlier studies (Table 2). Expression of the Atl protein by S. aureus iso-
late P was detected using specific polyclonal antibodies as mentioned in the Materials and
Methods (data not shown). As pro-Atl is the propeptide of the autolysin Atl, which was de-
tected by proteomic studies, pro-Atl was concluded to be expressed by both S. aureus strains
(our unpublished observations). The expression of the PSMα1-4 peptides has been detected in-
directly by using a plate assay in which cells of S. aureus isolates P or USA300 showed a spread-
ing phenotype on a soft agar plate, indicating that both strains produce the PSM peptides
(Table 2, data not shown). These data show that all antigens used in this study are produced
and secreted by S. aureus isolates P and USA300.
Detection of IgG responses against the selected antigens in EB patients
To assess the IgG responses against IsaA-His6, LytM-His6 and Nuc-His6, immunodetection
was performed using sera of healthy donors and EB patients (Fig. 2). From this analysis it is
clear that EB patients have, on average, a higher although variable IgG response against all
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three proteins in comparison to the healthy donors. The Atl propeptide was shown to be recog-
nized by antibodies present in sera of EB patients (our unpublished observations).
As the PSMα1 has previously been shown to be exposed on the cell surface of S. aureus, we
included the PSMα1, α2, α3, and α4 in an epitope mapping approach using the PepScan tech-
nology [38]. This analysis showed that 5 out of 7 EB patients have an above average titer of
IgGs against the peptides tested (Fig. 3). Three out of 7 plasma samples from EB patients
showed a very high reactivity against the N-terminal regions of the PSMα1, α2, and α3 pep-
tides. These results show that besides the IsaA-His6, LytM-His6 and Nuc-His6 proteins, the
PSM peptides are also well recognized by the humoral immune system.
Immunization with an octa-valent mixture of S. aureus antigens does not
reduce bacterial load in mice with S. aureus isolate P bacteremia
Groups of mice were immunized by subcutaneous injection with 5 μg of purified IsaA-His6,
LytM-His6, Nuc-His6, His6-pro-Atl, and PSMα1-4 each, emulsified in TiterMax Gold adjuvant
Fig 1. LDS-PAGE detection of the purified and dialyzed S. aureus antigens. Fifteen μg of LytM-His6 (1),
Nuc-His6 (2), IsaA-His6 (3) or His6-pro-Atl (4) was loaded. The molecular weight of marker proteins is
indicated (in kDa).
doi:10.1371/journal.pone.0116847.g001
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on day -70. On days -42 and -14, they were boosted with this mixture containing 25 μg of each
purified antigen. Blood samples were collected before and after immunization, and specific
serum IgG levels were determined by ELISA, demonstrating that these antigens generated hu-
moral immune responses to immunization (Fig. 4). The response against His6-pro-Atl was on
average 10-fold lower compared to the other 4 antigens.
Mice were challenged at day 0 with mild S. aureus isolate P bacteremia (n = 8 immunized
mice, n = 8 placebo-immunized mice), and animal discomfort and survival rate over 14 days
after infection were monitored. At day 14, surviving mice were sacrificed, and blood and organs
were removed for assessment of the bacterial load. In placebo-immunized mice, discomfort in-
creased, while animal survival declined over time. At day 14, 6 out of 8 placebo-immunized
mice were still alive. S. aureus load in kidneys of these mice was high, while bacterial load in
lungs and liver was low, and blood and spleen were culture negative (Fig. 5).
Compared to placebo-immunized animals, immunization with the octa-valent antigen mix-
ture did not reduce the S. aureus load in blood, lungs, spleen, liver, and kidneys (Fig. 5). Fur-
thermore, discomfort score and animal survival rate over 14 days did not differ between
immunized and placebo-immunized mice (data not shown).
Table 2. Proteins and peptides used in this study.
Name NCBI number / sequence* Function Identification antigen in Production Mw (dD) PI
isolate P USA300
IsaA-His6 SA2356 (N315) Transglycosylase (1) (2) E. coli 22.7 6.3
Nuc-His6 SA0746 (N315) Thermonuclease (1) (3) L. lactis 20.1 9.7
LytM-His6 SA0265 (N315) Glycyl-glycine endopeptidase (1) (3) L. lactis 33.1 6.4
His6-pro-Atl USA300HOU_0997 (USA300) Propeptide autolysin Atl Western (5) (1) L. lactis 19.4 7.9
PSMα1 MGIIAGIIKVIKSLIEQFTGKGGGGK$# Spreading/Toxin Spreading (6) (2)/(4) Synthetic 3.07 10.5
PSMα2 MGIIAGIIKFIKGLIEKFTGKGGGGK$# Spreading/Toxin Spreading (6) (2)/(4) Synthetic 3.09 10.7
PSMα3 MEFVAKLFKFFKDLLGKFLGNNGGGGK$# Spreading/Toxin Spreading (6) (2)/(4) Synthetic 3.41 10.4
PSMα4 MAIVGTIIKIIKAIIDIFAKGGGGK$# Spreading/Toxin Spreading (6) (2)/(4) Synthetic 2.98 10.6
* the sequences GGK$# stand for the addition of the GGG-Lys(ε-biotin) to each of the peptides
(1) Identified by proteomics [15]
(2) Identified by proteomics [17]
(3) Identified by proteomics (our unpublished observations)
(4) Identified using spreading assay [19]
(5) detection of Atl using specific antibodies (see Materials and Methods)
(6) Spreading as determined by plate assay (results not shown)
doi:10.1371/journal.pone.0116847.t002
Fig 2. Western detection of immune responses against the antigens IsaA-His6, LytM-His6 and Nuc-
His6. Sera of healthy volunteers (T7-1 till T7-6) and EB patients (EB51, 15, 01, 11, 09, 55) were used.
doi:10.1371/journal.pone.0116847.g002
Immunization with an Antigen Mixture in S. aureus Infection Models
PLOS ONE | DOI:10.1371/journal.pone.0116847 February 24, 2015 10 / 20
Immunization with an octa-valent S. aureus antigen mixture is not
protective against mortality due to S. aureus USA300 bacteremia in mice
To assess whether the lack of protective effect of immunization with the octa-valent mixture
was S. aureus strain-dependent, we included a lethal mouse model of MRSA bacteremia as
well. As immunized mice showed excellent IgG titers, the immunization schedule was not
adapted. In this model, mice were challenged with severe S. aureusUSA300 bacteremia (n = 8
immunized mice, n = 8 placebo-immunized mice), and animal discomfort and survival rate
over 14 days after infection were monitored. In placebo-immunized mice, discomfort in-
creased, while animal survival declined gradually over time, and at day 9, all placebo-immu-
nized mice had died (Fig. 6).
Fig 3. Heatmap of anti-PSMα1-4 reactivity. Plot of IgG responses from sera of volunteers (T7-1 till T7-4) and EB patients (EB01, 09, 51, 11, 15, 53, 02)
against the N- (1 to 15) and C- (7 to 21) terminal parts of the PSMα1-4 peptides. Colors represent a gradient of reactivity against the various peptides (green
is low and red is high). Peptides with a signal exceeding the median plus twice the standard deviation are boxed.
doi:10.1371/journal.pone.0116847.g003
Fig 4. IgG titers in serum of mice after immunization with the octa-valent mixture.Mice (n = 20) were
immunized subcutaneously with the mixture containing IsaA-His6, LytM-His6, Nuc-His6, His6-pro-Atl, and
PSMα1-4 at days -70 (5 μg of each antigen), days -42, and -14 (25 μg of each antigen). IgG titers on day -1
were assessed. Each symbol represents a single mouse. Median values are indicated by horizontal lines.
doi:10.1371/journal.pone.0116847.g004
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In this model of severe MRSA bacteremia, immunization with the octa-valent mixture con-
taining IsaA-His6, LytM-His6, Nuc-His6, His6-pro-Atl, and PSMα1-4 did not protect against
mortality due S. aureusUSA300 bacteremia (Fig. 6). Furthermore, the discomfort score over 14
days was not reduced, and higher IgG levels did not correlate with increased time-to-death of
mice (data not shown).
Immunization with an octa-valent S. aureus antigen mixture does not
protect against S. aureus isolate P skin infection
Absence of protection of the octa-valent mixture in S. aureus bacteremia does not exclude a
possible (lack of) protection in other types of S. aureus infections. To assess whether this anti-
gen mixture elicits a protective immune response against S. aureus skin infection, immunized
mice were challenged with S. aureus isolate P via the intradermal route (n = 4 immunized
mice, n = 4 placebo-immunized mice). Animal body weight and lesion size over 7 days after
Fig 5. Bacterial load in immunized mice with S. aureus isolate P bacteremia.Mice (n = 8) were immunized with the octa-valent vaccine containing IsaA-
His6, LytM-His6, Nuc-His6, His6-pro-Atl, and PSMα1-4, or with placebo. Animals were infected by intravenous inoculation of S. aureus isolate P (3 × 10
5
CFU). At day 14, surviving mice were sacrificed and quantitative cultures of blood, lungs, spleen, liver, and kidneys were performed. Each symbol represents
a single mouse. Median values are indicated by horizontal lines. Statistically significant differences in S. aureus load were not observed (P> 0.05; Mann-
Whitney U test).
doi:10.1371/journal.pone.0116847.g005
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infection were monitored. At day 7, mice were sacrificed and the S. aureus load in skin lesions
was assessed. In placebo-immunized mice, body weight loss over 7 days was minor, with a
maximum of 6.5%. Size of the skin lesion increased over time until 2.8–5.2 cm2 at day 7. At this
time point, median S. aureus load in the skin lesion was 2 × 108 CFU/cm2 (Fig. 7).
Compared to placebo-immunized mice, immunization with the octa-valent antigen mixture
did not limit the body weight loss over time (Fig. 7A), while size of the skin lesion was reduced
in immunized mice (Fig. 7B). S. aureus load in skin lesions at day 7 was not reduced in immu-
nized mice (Fig. 7C). As reduction of the bacterial load in the skin lesion was our primary out-
come measure, we concluded that immunization with the octa-valent S. aureus antigen
mixture did not protect against S. aureus isolate P skin infection.
Discussion
In view of the high mortality rates of S. aureus infections [42–45], the emergence of antibiotic-
resistant S. aureus strains [6] and the lack of new antimicrobials in the development pipeline
[8], alternative treatment strategies for S. aureus infections are urgently needed. One approach
is treatment through immunization targeting S. aureus antigens. This may be an interesting
substitute for or additive to the currently used antibiotics. A role of certain anti-staphylococcal
antibodies in protection against S. aureus infection-related death is suggested by a number of
studies in humans [14,26,46,47]. Next to these suggestions from clinical studies, a number of
studies in S. aureus-infected experimental animals showed protective effects of active or passive
immunization. Notwithstanding these promising results obtained in experimental animals, no
efficacy of immunization is observed in clinical studies [9–11].
The lack of protective capacity of anti-staphylococcal immunization may be explained by,
for example, a lack of power of several clinical studies [12,13], the limited number of S. aureus
antigens targeted in these studies (mostly one or two), or the S. aureus infection studied (most-
ly bacteremia/sepsis). In addition, the apparent lack of success of immunization targeting for
example CP5 and CP8 [48,49], IsdB [50], or ClfA [51] in S. aureus-infected patients may be re-
lated to the choice of targets for immunization. Therefore, in the present study, we selected S.
Fig 6. Survival of immunized mice with S. aureus USA300 bacteremia.Mice (n = 8) were immunized
with the octa-valent vaccine containing IsaA-His6, LytM-His6, Nuc-His6, His6-pro-Atl, and PSMα1-4, or with
placebo. Animals were infected by intravenous inoculation of S. aureusUSA300 (6 × 105 CFU), and were
monitored for 14 days. A statistically significant difference in animal survival rates was not observed (P> 0.05;
log rank test).
doi:10.1371/journal.pone.0116847.g006
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Fig 7. Course of infection in immunized mice with S. aureus isolate P skin infection.Mice (n = 4)
were immunized with the octa-valent vaccine containing IsaA-His6, LytM-His6, Nuc-His6, His6-pro-Atl, and
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aureus antigens that are accessible for antibodies based on proteomic analysis of exoproteomes
of S. aureus [15] and a proteolytic shaving approach of S. aureus [17]. This strategy resulted in
the selection of IsaA, LytM, Nuc, pro-Atl, and PSMα1-4 as targets for active immunization.
Previous studies showed that these eight S. aureus antigens are immunogenic in humans
[14,26,29,30], and may therefore be applicable in the clinical setting. Moreover, monoclonal
antibodies against IsaA enhance the killing of S. aureus in whole blood samples from healthy
subjects and patients prone to staphylococcal infections [52], and passive immunization with
these monoclonal antibodies can lead to protection against S. aureus infections in mice [28,53].
Using the hosts L. lactis and E. coli, all selected S. aureus antigens (IsaA, LytM, Nuc, and
pro-Atl) were successfully isolated. No major degradation products were observed after isola-
tion, and IsaA-His6, LytM-His6, and Nuc-His6 fusion proteins were all biologically active after
purification, indicating they had retained their natural conformation. In addition, these three
fusion proteins as well as the PSMα1-4 peptides were well recognized by IgG present in plasma
of healthy volunteers and EB patients. These results indicate that His-tagged fusions did not af-
fect binding of IgG to these antigens. In addition, in a previous study, it has been shown that
the Atl propeptide is recognized by antibodies present in sera of EB patients (our unpublished
data).
The potentially protective capacity of immunization was evaluated in mice immunized with
a mixture of IsaA, LytM, Nuc, pro-Atl and PSMα1-4. In the use of an octa-valent antigen cock-
tail we followed the approach of Stranger-Jones et al. [54], who immunized mice with IsdA,
IsdB, SdrD, and SdrE, either in a combination or individually. They observed that single anti-
gen immunization elicited no or only very modest protection against S. aureus abscess forma-
tion or S. aureus lethal challenge, whereas immunization with the cocktail completely
protected in both S. aureus infections. In addition, Bagnoli et al. proposed a model in which
vaccine efficacy is gained via antibodies that directly inhibit bacterial viability and/or toxicity,
via antibodies to mediate opsonophagocytosis, and via cell-mediated immunity to stimulate re-
cruitment of phagocytes at the site of infection [55]. For this purpose, multiple S. aureus anti-
gens with different functions should be targeted. In the present study immunization of mice
with the octa-valent antigen mixture of IsaA, LytM, Nuc, pro-Atl and PSMα1-4 resulted in de-
tectable IgG responses against all eight antigens. Although anti-pro-Atl levels were slightly
lower, all observed IgG levels were in the expected range [54,56]. This observation indicated
that all antigens were recognized well by the immune system of the mice.
After the final booster immunization, mice were infected with S. aureus. Clinically relevant
models were used: mild bacteremia by S. aureus isolate P (MSSA), lethal bacteremia by S. aure-
us USA300 (MRSA), and transient S. aureus isolate P skin infection. It was shown that active
immunization with the octa-valent mixture of IsaA-His6, LytM-His6, Nuc-His6, His6-pro-Atl,
and PSMα1-4, although resulting in high anti-staphylococcal IgG levels, did not protect mice
against mild S. aureus isolate P bacteremia, severe S. aureusUSA300 bacteremia, or S. aureus
isolate P skin infection.
The lack of protection by active immunization with the octa-valent S. aureus antigen mix-
ture in our mouse infection experiments may be related to the study design or the presumed
role of anti-staphylococcal antibodies in protection against these S. aureus infections. Regard-
ing the study design, the S. aureus isolates used and the type of S. aureus infections studied are
PSMα1-4, or with placebo. Animals were infected by intradermal inoculation of S. aureus isolate P (3 × 107
CFU), and were monitored for 7 days. (A) Animal body weight over time after S. aureus skin infection was not
affected by vaccination (P> 0.05; Quade’s rank analysis of covariance). (B) Lesion size was significantly
reduced by vaccination, as indicated by the asterisk (P = 0.005; Quade’s rank analysis of covariance). (C) S.
aureus load in the skin lesion at day 7 was not reduced by vaccination (P> 0.05; Mann-Whitney U test).
doi:10.1371/journal.pone.0116847.g007
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clinically relevant [15,31,32]. Other investigators used these infection models as well, and dem-
onstrated that active or passive immunization targeting S. aureus antigens can lead to protec-
tion in mice [9–11]. In addition, both S. aureus strains produced all eight S. aureus antigens. It
should be noted that preclinical animal models of S. aureus infection do not fully mimic the
natural S. aureus infection process in humans due to various differences among which differ-
ences in host cell proteins such as hemoglobin [57] and the requirement for high bacterial inoc-
ula [58] in the non-human host. Despite these limitations of experimental animal models, we
conclude that failure to show protective activity upon active immunization can presumably not
be explained by the choice of S. aureus strains or the choice of infection models. As the ob-
served differences between immunized mice and placebo-immunized mice were not signifi-
cant, not even borderline, increasing the group sizes will probably not result in significant
differences. Therefore, this cannot clarify the failure of immunization in our in vivomodels.
A more plausible explanation for the lack of protection of the octa-valent antigen mixture in
the present study may be related to the presumed role of anti-staphylococcal antibodies in pro-
tection against S. aureus infection. Although previous studies suggested a role of anti-staphylo-
coccal antibodies in protection against death in S. aureus carriers [14,26,46,47,56,59], their role
may be overestimated. Possibly, IgG against IsaA-His6, LytM-His6, Nuc-His6, His6-pro-Atl,
and PSMα1-4, or anti-staphylococcal IgG in general, has no or only a limited role in protection
against S. aureus infections. It may be conceivable that antibodies against S. aureus antigens in
humans are just a result of prior exposure in carriers and non-carriers, via S. aureus coloniza-
tion or previous (sub)clinical S. aureus infection, while their protective capacity is limited. Pre-
vious exposure to S. aureus in carriers may also result in improved cellular immunity, which
could also protect against S. aureus infection-related death, as was already suggested by Joshi
et al. [60]. Beside this, the production of virulence factors such as toxins and immune evasion
proteins by S. aureus [61,62] might overwhelm the generated humoral immune response. An-
other reason for the failure of the octa-valent antigen mixture to protect mice against S. aureus
infection might be related to a potential immunosuppression induced by one of the antigens in
the cocktail. As other combinations of S. aureus antigens were not tested, conclusions in this re-
spect cannot be drawn.
Although passive immunization with monoclonal antibodies against IsaA protected mice
against S. aureus infection [28,53], in the present study no protection was obtained after active
immunization with a mixture including IsaA. A possible explanation for this discrepancy may
be related to insufficient binding of polyclonal antibodies induced by active immunization to
relevant epitopes of IsaA in order to provide protection against S. aureus infection, in contrast
to the monoclonal antibodies administered by passive immunization, clearly binding to rele-
vant epitopes of IsaA.
In conclusion, active immunization with an octa-valent mixture containing IsaA-His6,
LytM-His6, Nuc-His6, His6-pro-Atl and the PMSα1–4 peptides does not protect mice against
S. aureus bacteremia and S. aureus skin infection. The observations suggest that these polyclon-
al anti-staphylococcal antibodies do not provide protection against S. aureus infection. Conse-
quence of the present study should not be abandoning of research focusing on immunization
in S. aureus infections, as other investigators obtained promising results in this respect. Instead,
future research should focus on novel treatment strategies combining immunization with anti-
biotic treatment and/or cytokine administration.
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